编者按：每隔五年，上海市政府都会选择一个特定的时间，停下来审视已经取得的成绩和尚需开展的工作。而上周闭幕的上海市第十一次党代会则标志着新一轮工作的开始。大会报告将成为制定经济、贸易、商业、技术和金融政策的基础，并勾勒出承载城市未来梦想的广阔愿景。相关决定对中国本土和外籍人士的工作和家庭生活都将产生深远的影响。在本系列文章中，我们邀请了居住在上海的本土和外籍人士分享他们对上海发展和未来前景的看法。
2009年，已在美国生活22年的张炜被调往新加坡工作。2011年7月，张炜被任命为诺华旗下非专利药和生物类似药业务——山德士（中国）总裁，举家迁往上海。去年10月，他又被任命为诺华集团（中国）副总裁，兼任公共事务和企业责任负责人。
诺华集团（中国）副总裁张炜
能否谈一下您在上海的工作和个人生活？
我在诺华集团（中国）工作，负责公共事务和企业责任项目。我和妻子，还有三个孩子居住在上海，一个是5岁，一个是8岁，还有一个是10岁。空闲的时候，我喜欢滑雪、读书还有听音乐。一想到上海，我脑海里就会浮现出“创新、多元、包容、活力”这些字眼。
过去五年来，上海有哪些变化给您留下了最深的印象？
印象最深的是创新的步伐越来越快。现在，创新已深入社区和个人，涉及上海整体发展的方方面面。上海已然成为市场改革、制度创新和创业精神方面的先行者。创新意识已深深扎根于上海市民心中。
上海市政府希望将其建设成具有全球影响力的科技创新中心，您是如何看待这一目标的？
上海在科技创新发展方面取得了长足的进步。市政府也积极落实各项政策法规，包括实施张江生物制药进口试点项目等举措来鼓励创新。对国内外顶端专业研发人才来说，上海已成为一块颇具吸引力的“磁石”。
五年来，诺华在中国尤其是在上海取得了哪些突破？
诺华致力于探索改善生活质量、延长人类寿命的新方法。在中国，我们一直希望能凭借多元化的产品组合、对当地的巨大投入以及与多方之间建立的互信合作关系，对人们的健康福祉发挥积极的影响。
近年来，上海市政府推出了多项举措来促进医药行业的发展，比如针对高价值药品创新支付模式的尝试。这一模式的建立对诺华等医药企业产生了深远的影响。它不仅能确保当地居民获得创新药物，还能提高医药企业的创新热情，为创新开拓更广阔的前景。
上海具有哪些独特的机遇或挑战？
上海聚集了很多的重点大学、研究机构、医院和专业人才，这是当地特有的优势。上海拥有六个生物医药产业基地，其中包括中国规模最大的新药研发中心——张江高科技园区，还有一批高品质实验室。这里已经成为一个蓬勃发展的全球性资本、产业和人才平台，因此也势将成为世界领先的创新和科技中心。医药行业是一个复杂的行业，需要多个相关方通力合作。最大的问题在于如何创建和实施一套适宜的医药创新生态系统，实现政府、医药公司、医院、医疗保险公司等各相关方的无缝对接，推进医药创新，完善创新药的采购和支付机制。
能否跟我们分享一下诺华上海研发园区相关的运营信息？
诺华的研发园区位于张江高科技园区，是诺华全球第三大研发中心，同时也有力地证明了我们对中国的坚定承诺。园区的工作让我们可以及时应对当地不断变化的医疗需求，同时也可以以此为中心与当地的研究机构分享专业知识和经验。
对于上海未来五年的发展，您有哪些建议？
上海近年来已经取得了飞速的发展。为了未来五年的进一步发展，希望上海继续营造适宜人才发展和开放交流的环境，加大研发投入，完善监管体系，同时建立能激励创新的、可持续的市场准入制度。
本文原文是英文，中文翻译来源于诺华。以下英文原文刊载于2017年5月17日《上海日报》，作者丁依柠
A 'magnet' for research and development
Ding Yining
Editor's note:
Every five years, Shanghai stops to take stock of what it has accomplished and what more needs to be done. The conclusion of the 11th Congress of the Chinese Communist Party of Shanghai last week marks the process anew. Its report card will help shape economic, trade, commercial, technology and financial policies, and outline the broad visions that carry the city's dreams for the future. The work and home lives of local Chinese and expatriates alike will be affected by those decisions. In this series, we ask foreigners living in the city to share their views on Shanghai's progress and future prospects.
After living in the US for 22 years, Larry Zhang was posted to Singapore in 2009 for a working assignment. He and his family moved to Shanghai in July 2011 after Zhang was appointed chief executive officer of Novartis Sandoz China. Last October, he was named vice president, head of public affairs and corporate responsibility, Novartis Group(China).
Larry Zhang
Vice President, Novartis Group(China)
Q: Can you tell us a bit about your personal life and career in Shanghai?
A: I work for Novartis Group(China), involved with public affairs and corporate responsibility programs. My wife and I have three children, aged 5, 8 and 10. In my free time, I love to ski, read and listen to music. When I think of Shanghai, the words "innovation, diversity, inclusion and vibrancy" come to mind.
Q: What changes in Shanghai in the past five years have impressed you most?
A: The accelerated pace of in novation. Nowadays, innovation has expanded to overall development of this city, down to communities and individuals. Shanghai has become a pioneer of market reform, institutional innovation and entrepreneurship. Innovation is rooted in the mindset of Shanghai citizens.
Q: The Shanghai government want to build the city into a global hub for research and development, view that goal?
A: Shanghai has made remarkable progress in its development of innovation in science and technology. Policies and regulations has been implemented to nurture innovation, including initiatives like the biological import pilot project in Zhangjiang. Shanghai has become a magnet for research and development professional talents from both home and abroad.
Q: In the past five years, what are the breakthroughs Novartis has achieved in China, especially in Shanghai?
A: Novartis is committed to the discovery of new ways to improve and extend people's lives. In China, we are devoted to making a positive impact on the health and well-being of people, with our diversified portfolios, strong local investment and trusted partnerships with multiple stakeholders.
In recent years, the Shanghai government has unveiled many initiatives to advance the development of the healthcare industry. The establishment of innovative access models is one example that has had a profound impact for the industry players like Novartis. Il not only ensures local citizens the access to the innovative drugs, but it also promotes greater enthusiasm and prospects for innovation in pharmaceutical sector.
Q: What unique opportunities or challenges does Shanghai offer?
A: Shanghai’s unique advantages include the concentration of leading universities, research institutions, hospitals and professional talent. The city has six biomedical industrial bases, including Zhangjiang High-Tech Park, the largest new drug research and development center in China, along with a number of high-quality laboratories. Shanghai has become a thriving global platform for capital, industry and talent, making the city well positioned to become a world-leading center of innovation, science and technology. The healthcare industry is complex. The key challenge lies in how to create and implement an ecosystem so that stakeholders like the government, pharmaceutical companies, hospitals and medical insurance companies can work seamlessly to advance medical innovation and reimbursement models.
Q: Could you please share with us some information about the operation of the Novartis research and development campus in Shanghai?
A: The campus, located in the Zhangjiang Science Park, marks Novartis1 third main hub for drug research and is strong testament to our deep commitment to China. The campus enables us to address evolving local health needs in a more prompt manner. It also serves as a hub for sharing our expertise with local research institutions.
Q： What should Shanghai doto make even greater progress in the next five years?
A: Shanghai has witnessed tremendous progress in recent few years. To make I he upcoming five years even better, we would suggest the city promote an environment that develops talent and open communications, invest in research and development, ensure a vell-designed regulatory system, and create a sustainable market access system that rewards innovation.
点击下方“阅读原文”查看英文原文
